Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|12|1|57-69

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.12, Iss.1, 2011-01, pp. : 57-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease

By Brophy Donald F   Ripley Elizabeth BD   Holdford David A  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1461-1469

Informa Healthcare

Access to resources Recommend Favorite

Effects of silymarin on biochemical and oxidative stress markers in end‐stage renal disease patients undergoing peritoneal dialysis

By  

Hemodialysis International, Vol. 20, Iss. 4, 2016-10 ,pp. : 558-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations

By Abraham Ivo   MacDonald Karen  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 885-887

Informa Healthcare

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite